Virpax Pharmaceuticals Inc (VRPX) Return on Assets ROA from the fourth quarter of 2024 to fourth quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Dec 31 2024 to Dec 31 2023 - CSIMarket
Virpax Pharmaceuticals Inc 's ROA from the fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Virpax Pharmaceuticals Inc 's ROA in the fourth quarter of 2024?
Virpax Pharmaceuticals Inc recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on assets (ROA) of -636.72%.
However, within the Healthcare sector 1080 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2024 from 4963 to 5669.
: Virpax Pharmaceuticals, Inc. has made significant strides in the development of Probudur, a long-acting liposomal bupivacaine formulation. Recent results from a dose range finding study conducted in a minipig model indicate potential for effective pain management. However, these advancements come amidst a challenging financial landscape, as the company reported a year-over-year revenue decrease despite growth in the broader market. This article reviews the preclinical findings of Probudur and contextualizes them within the competitive landscape of pharmaceutical revenue trends. Virpax Pharmaceuticals is at the forefront of developing non-addictive products aimed at addressing pain management, central nervous system (CNS) disorders, and related health conditions. Their latest innovation, Probudur, which utilizes a novel liposomal formulation to deliver bupivacaine, represents a breakthrough in sustained pain relief an area of critical need in both postoperative care and chronic pain management. Dose Range Finding Study: The recent dose range finding (DRF) study conducted with minipigs has yielded promising results for Probudur. The study aimed to determine the optimal dosage and assess the pharmacokinetics and pharmacodynamics of the formulation when injected at a surgical wound site. Findings indicate that Probudur is capable of providing both immediate and prolonged analgesic effects, which could significantly enhance patient care outcomes following surgery or traumatic injury. The minipig model is particularly relevant, as it closely resembles human responses to pain medications in terms of physiology and drug metabolism, providing a more accurate reflection of potential clinical outcomes. The study results may facilitate further clinical trials and regulatory approval processes, paving the way for enhanced pain management solutions in the healthcare market.
Virpax Pharmaceuticals Announces Encouraging Results for Probudur Amidst Financial Challenges BERWYN, Pa. In a significant step towards advancing its innovative product pipeline, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced positive outcomes from a Dose Range Finding (DRF) study conducted on Probudur, a long-acting liposomal bupivacaine formulation. This compound is designed to be injected directly into a wound site, offering both immediate and extended pain relief. The company specializes in non-addictive solutions for pain management, post-traumatic stress disorder (PTSD), central nervous system (CNS) disorders, and antiviral barriers. Probudur s Promising ResultsThe recent study involved minipigs as a model and aimed to determine the optimal dosage range for Probudur s effectiveness and safety. The findings demonstrated that Probudur could significantly reduce pain post-surgery, marking a pivotal advancement in the field of postoperative care. Given the rising concerns about the opioid crisis and the need for non-addictive pain management alternatives, Probudur holds promise for a safer option in treating postoperative pain.
Virpax Pharmaceuticals, Inc. a preclinical-stage pharmaceutical company headquartered in Berwyn, Pennsylvania, has announced the successful closing of a public offering amounting to $5.0 million. The offering included shares of the Company s common stock, with a par value of $0.00001 per share, as well as pre-funded warrants that enable the purchase of additional shares at a public offering price of $0.50 per share, less a nominal deduction for the par value.Established with a focus on innovative and proprietary drug delivery systems, Virpax is primarily engaged in developing solutions to address various pain indications. This recent fundraising initiative aims to support the Company s ongoing research and development efforts, particularly as it aims to expand its portfolio of drug delivery technologies.
In the rapidly evolving pharmaceutical sector, the operational and financial status of companies significantly influences their market performance, investor confidence, and strategic growth potential. Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) has recently captured the attention of investors and market analysts due to its notable stock fluctuations, strategic financial maneuvers, and promising developments in pain management product lines. This article thoroughly reviews recent news surrounding Virpax Pharmaceuticals, including stock performance, insider ownership, loan financing, share issuance, and product development disclosures. Stock Performance and Market PositionAs of July 19, 2024, Virpax Pharmaceuticals Inc. was trading approximately 83.00% below its 52-week high, a stark indication of the stock s volatility and the challenges the company faces in gaining traction in a competitive market. One key metric contributing to market sentiment is insider ownership, which rests at approximately 10.99%. Since institutional investors hold a mere 0.03% of shares, market confidence appears relatively low. This limited engagement from both insiders and financial institutions may raise concerns regarding the company s investment attractiveness.
In the dynamic landscape of pharmaceutical investments, companies often experience turbulent phases shaped by regulatory compliance, funding activities, and investors’ responses to clinical trial results. An interesting case study is that of Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), which has recently navigated a series of developments that underscore both the vulnerabilities and resilience inherent in pharmaceutical stock performance. This article analyzes noteworthy recent events concerning Virpax Pharmaceuticals, their implications, and their broader significance within the pharmaceutical sector. Recent Developments1. Compliance with Nasdaq Minimum Bid Price : On July 24, 2024, Virpax announced that it had regained compliance with Nasdaq’s minimum bid price requirement, necessitating a closing price of $1.00 or greater for 10 consecutive business days. This compliance was critical for maintaining its listing on the Nasdaq exchange, reflecting the infrastructure that sustains investor confidence and market capitalization.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
